MONALEESA-3 A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor Carcas, Page Rev. April 18, 2022 4 positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment.